Andres Maldonado

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) received reaffirmed buy ratings from both H.C. Wainwright and Oppenheimer this week, with analysts citing the company's diversified pipeline as a key driver for future growth, despite a sharp stock decline after Novo Nordisk‘s (NYSE:NVO) mid...